HomeCompareZGNX vs EQR

ZGNX vs EQR: Dividend Comparison 2026

ZGNX yields 7.50% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EQR wins by $14.9K in total portfolio value· pulled ahead in Year 3
10 years
ZGNX
ZGNX
● Live price
7.50%
Share price
$26.68
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.8K
Annual income
$1,205.70
Full ZGNX calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ZGNX vs EQR

📍 EQR pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodZGNXEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ZGNX + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ZGNX pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ZGNX
Annual income on $10K today (after 15% tax)
$637.18/yr
After 10yr DRIP, annual income (after tax)
$1,024.85/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, EQR beats the other by $3,629.42/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ZGNX + EQR for your $10,000?

ZGNX: 50%EQR: 50%
100% EQR50/50100% ZGNX
Portfolio after 10yr
$40.3K
Annual income
$3,340.65/yr
Blended yield
8.29%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ZGNX right now

ZGNX
Analyst Ratings
16
Buy
6
Hold
Consensus: Buy
Price Target
$26.00
-2.5% upside vs current
Range: $26.00 — $26.00
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ZGNX buys
0
EQR buys
0
No recent congressional trades found for ZGNX or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricZGNXEQR
Forward yield7.50%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$32.8K$47.8K
Annual income after 10y$1,205.70$5,475.61
Total dividends collected$9.8K$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold
Analyst price target$26.00$70.35

Year-by-year: ZGNX vs EQR ($10,000, DRIP)

YearZGNX PortfolioZGNX Income/yrEQR PortfolioEQR Income/yrGap
1$11,450$749.63$11,380$679.82+$70.00ZGNX
2$13,053$802.14$13,014$837.25+$39.00ZGNX
3← crossover$14,822$854.66$14,961$1,036.20$139.00EQR
4$16,766$906.96$17,297$1,289.22$531.00EQR
5$18,899$958.83$20,121$1,613.15$1.2KEQR
6$21,232$1,010.08$23,561$2,030.84$2.3KEQR
7$23,778$1,060.53$27,783$2,573.54$4.0KEQR
8$26,553$1,110.04$33,013$3,284.39$6.5KEQR
9$29,570$1,158.47$39,547$4,223.51$10.0KEQR
10$32,846$1,205.70$47,791$5,475.61$14.9KEQR

ZGNX vs EQR: Complete Analysis 2026

ZGNXStock

Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.

Full ZGNX Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ZGNX vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ZGNX vs SCHDZGNX vs JEPIZGNX vs OZGNX vs KOZGNX vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.